FacebookTwitterGoogle+RedditEmail

Tremendous Waste in Medicare Diabetes Drugs Revealed

by MARTHA ROSENBERG

Walid Gellad, M.D., M.P.H. is an assistant professor of medicine at the University of Pittsburgh, and a staff physician and researcher at the Pittsburgh VA Medical Center.  His research focuses on physician prescribing practices and on policy issues affecting access to medications for patients. He recently granted this interview with CounterPunch reporter Martha Rosenberg.

Martha Rosenberg: Your study in the Annals of Internal Medicine’s July 16 issue [Brand-Name Prescription Drug Use Among Veterans Affairs and Medicare Part D Patients With Diabetes] compares the use of brand name diabetes drugs in Medicare and the VA and concludes that one billion dollars a year could be saved a year if Medicare adopted the VA’s prescribing habits.

Walid Gellad: Yes we looked at diabetes-related medications like oral hypoglycemics, insulins, statins and ACE inhibitors and found that use of brand-name drugs was much greater in Medicare than the VA in almost every region of the country–two to three times as high as Medicare.

Rosenberg: When you started this research, did you expect such dramatic findings?

Gellad: I expected rates would be higher in Medicare, but didn’t realize they would be so much higher. As a VA doctor, I often see veterans who have outside insurance but still come to the VA to get cheaper drugs. For example, some patients might come in to get Lipitor at the discounted, VA price, but they didn’t realize they could switch drugs to get a less expensive, generic instead–one that could be filled outside the VA.

Rosenberg: Can you explain the difference between the two agencies’ prescribing systems?

Gellad: Medicare uses over 1,000 private plans with distinct formularies to administer its drug benefit, whereas the VA administers its own benefit using one national formulary. All veterans face the same low cost sharing, and benefits are managed by a central pharmacy benefits manager which has substantially lowered pharmacy spending for the VA.

Rosenberg: You write that previous studies have compared medication pricesbetween the VA and Medicare but not medication choices and cite the VA’s promotion of therapeutic substitution. Can you explain?

Gellad: That’s rightand medication choice is just as important for controlling spending as price is.  In this paper we look at what might happen to spending if price actually stays the same, but we changed the drugs prescribed. Unlike generic substitution in which a generic drug might be switched for a brand drug like simvastatin for Zocor [the generic and brand names of the same drug] therapeutic substitution, done by a clinician, interchanges generic drugs that are in the same class but not identical to the brand drug–for example, generic simvastatin might be substituted for the brand name atorvastatin which is Lipitor.

Rosenberg: Another factor you cite in cost savings is the lack of visits of drug reps to the VA.

Gellad: That is one potential factor, yes. Most VA doctors are not visited by pharmaceutical sales representatives and do not give out free samples. We are also a salaried workforce and it may be possible that doctors who are willing to accept salaries have a different perspective on marketed drugs.

Rosenberg: You write that private Part D plans can lose market share if they don’t offer the popular, brand name drugs. Yet those are the exact drugs that inflate costs!

Gellad: Yes, it was thought that if the Part D plans had to compete to get members they will keep prices lower, but the flip side is they need to offer the drugs patients are asking for if they want Medicare beneficiaries to enroll.

Rosenberg: If government administered plans produce such cost savings, what is the appeal of private plans?

Gellad: The appeal of having many private plans administer the drug benefit is that competition between them presumably will offer patients more choices and better prices, in a well functioning marketMany people would not accept a central government authority making decisions about drugs available to them. It turns out, however, that all drugs are available to individuals receiving benefits through VA, it’s just that in some cases physicians have to make a good case for why they are needed.  I am not proposing Medicare turn into the VA, but the truth is that financial resources for Medicare are limited. Money spent in one place that is not needed cannot be spent in another. There can’t be a medical reason that so many more patients on Medicare need brand name drugs compared to those than at the VA.

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

Martha Rosenberg is an investigative health reporter. She is the author of  Born With A Junk Food Deficiency: How Flaks, Quacks and Hacks Pimp The Public Health (Prometheus).

More articles by:

CounterPunch Magazine

minimag-edit

bernie-the-sandernistas-cover-344x550

zen economics

Weekend Edition
December 09, 2016
Friday - Sunday
Jeffrey St. Clair
Roaming Charges: Nasty As They Wanna Be
Henry Giroux
Trump’s Second Gilded Age: Overcoming the Rule of Billionaires and Militarists
Andrew Levine
Trump’s Chumps: Victims of the Old Bait and Switch
Chris Welzenbach
The Forgotten Sneak Attack
Lewis Lapham
Hostile Takeover
Joshua Frank
This Week at CounterPunch: More Hollow Smears and Baseless Accusations
Paul Street
The Democrats Do Their Job, Again
Vijay Prashad
The Cuban Revolution: Defying Imperialism From Its Backyard
Michael Hudson - Sharmini Peries
Orwellian Economics
Erin McCarley
American Nazis and the Fight for US History
Mark Ames
The Anonymous Blacklist Promoted by the Washington Post Has Apparent Ties to Ukrainian Fascism and CIA Spying
Yoav Litvin
Resist or Conform: Lessons in Fortitude and Weakness From the Israeli Left
Conn Hallinan
India & Pakistan: the Unthinkable
Andrew Smolski
Third Coast Pillory: Nativism on the Left – A Realer Smith
Joshua Sperber
Trump in the Age of Identity Politics
Brandy Baker
Jill Stein Sees Russia From Her House
Katheryne Schulz
Report from Santiago de Cuba: Celebrating Fidel’s Rebellious Life
Nelson Valdes
Fidel and the Good People
Norman Solomon
McCarthy’s Smiling Ghost: Democrats Point the Finger at Russia
Renee Parsons
The Snowflake Nation and Trump on Immigration
Margaret Kimberley
Black Fear of Trump
Michael J. Sainato
A Pruitt Running Through It: Trump Kills Nearly Useless EPA With Nomination of Oil Industry Hack
Ron Jacobs
Surviving Hate and Death—The AIDS Crisis in 1980s USA
David Swanson
Virginia’s Constitution Needs Improving
Louis Proyect
Narcos and the Story of Colombia’s Unhappiness
Paul Atwood
War Has Been, is, and Will be the American Way of Life…Unless?
John Wight
Syria and the Bodyguard of Lies
Richard Hardigan
Anti-Semitism Awareness Act: Senate Bill Criminalizes Criticism of Israel
Kathy Kelly
See How We Live
David Macaray
Trump Picks his Secretary of Labor. Ho-Hum.
Howard Lisnoff
Interview with a Political Organizer
Yves Engler
BDS and Anti-Semitism
Adam Parsons
Home Truths About the Climate Emergency
Brian Cloughley
The Decline and Fall of Britain
Eamonn Fingleton
U.S. China Policy: Is Obama Schizoid?
Graham Peebles
Worldwide Air Pollution is Making us Ill
Joseph Natoli
Fake News is Subjective?
Andre Vltchek
Tough-Talking Philippine President Duterte
Binoy Kampmark
Total Surveillance: Snooping in the United Kingdom
Guillermo R. Gil
Vivirse la película: Willful Opposition to the Fiscal Control Board in Puerto Rico
Patrick Bond
South Africa’s Junk Credit Rating was Avoided, But at the Cost of Junk Analysis
Clancy Sigal
Investigate the Protesters! A Trial Balloon Filled With Poison Gas
Pierre Labossiere – Margaret Prescod
Human Rights and Alternative Media Delegation Report on Haiti’s Elections
Charles R. Larson
Review:  Helon Habila’s The Chibok Girls: the Boko Haram Kidnappings and Islamist Militancy in Nigeria
David Yearsley
Brahms and the Tears of Britain’s Oppressed
FacebookTwitterGoogle+RedditEmail